Long-Term Outcomes of Previously Treated Adult and Adolescent Patients with Severe Hemophilia A Receiving Prophylaxis with Extended Half-Life FVIII Treatments: An Economic Analysis from a United Kingdom Perspective

BACKGROUND: The standard of care for patients with hemophilia A is prophylaxis with factor VIII (FVIII) therapies. Extended half-life (EHL) FVIII products offer a reduced infusion burden compared with standard FVIII treatments. However, comparative evidence between EHLs is lacking. OBJECTIVE: To dev...

Descripción completa

Detalles Bibliográficos
Autores principales: Benson, Gary, Morton, Tim, Thomas, Huw, Lee, Xin Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822074/
https://www.ncbi.nlm.nih.gov/pubmed/33500640
http://dx.doi.org/10.2147/CEOR.S280574

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7822074/
https://www.ncbi.nlm.nih.gov/pubmed/33500640
http://dx.doi.org/10.2147/CEOR.S280574

Ejemplares similares